IL22 and cervical carcinoma: It acts by secreting protease IV (PIV) and inactivating interleukin 22 (IL-22) in order to disrupt the mucosal defense against extracellular pathogens (Bradshaw et al., 2018), providing opportunities for HPV infection, then promote the occurrence of cervical cancer.